Advertisement

Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study

  • Zhi-Xiang Huang
  • Wei-Ming Deng
  • Xin Guo
  • Zheng-Ping Huang
  • Yu-Kai Huang
  • Chu-Lan Lin
  • Tian-Wang LiEmail author
Original Article

Abstract

Objectives

Hip arthritis plays a critical role in the prognosis of ankylosing spondylitis (AS). Dose reduction of tumor necrosis factor inhibitors preserves general improvement of AS, so this study attempted to examine the equivalence between Yisaipu® tapering and conventional therapy for hip arthritis in AS patients, using clinical parameters and magnetic resonance image (MRI).

Methods

AS patients received this etanercept-biosimilar injections (50 mg/week) in the first 12 weeks. Participants in the tapering group were treated with this reagent 50 mg every other week from week 13 to week 24, while the control group kept undergoing full-dose therapy. Clinical and laboratory parameters were assessed at baseline, week 12 and week 24. MRI examination of hip was performed at baseline and week 24.

Results

One hundred and thirty-six patients were enrolled, and 80 of them were in the tapering group. Linear mixed model revealed that main effects of tapering group with control group as reference in disease activity parameters were insignificant (p > 0.05). Main effects of baseline with week 24 as reference were significant (p < 0.05), but main effects of week 12 with week 24 as reference were not (p > 0.05). Prevalence of acute inflammatory change in MRI significantly decreased in the tapering group (76.88% vs 20.00%, p < 0.05) and control group (76.79% vs 19.64%, p < 0.05). Influence of both treatments on acute inflammatory change was equivalent (p > 0.05).

Conclusion

Efficacy of Yisaipu® tapering treatment is comparable to the full-dose therapy for hip arthritis in AS patients. Both treatments maintain remission of hip arthritis after patients achieved low disease activity.

Keywords

Ankylosing spondylitis Dose reduction Etanercept-biosimilar Hip MRI 

Notes

Acknowledgements

The authors thank Prof. Jun Yang from the Jinan University, for his statistical advice.

Funding

This work was supported by the Natural Science Foundation of Guangdong Province (No. 2017A030313526), Research Foundation for the Introduction of Talent, Guangdong Second Provincial General Hospital (No. 2014001), and Medical Scientific Research Foundation of Guangdong Province (No. A2015517).

Compliance with ethical standards

This study was approved by the ethics committee of Guangdong second provincial general hospital (2015-KLYY-0015). Written informed consents in accordance with the declaration of Helsinki were given by participants.

Disclosures

None.

References

  1. 1.
    Jeong H, Eun YH, Kim IY, Kim H, Lee J, Koh EM, Cha HS (2017) Characteristics of hip involvement in patients with ankylosing spondylitis in Korea. Korean J Intern Med 32(1):158–164.  https://doi.org/10.3904/kjim.2015.229 CrossRefPubMedGoogle Scholar
  2. 2.
    Huang ZG, Zhang XZ, Hong W, Wang GC, Zhou HQ, Lu X, Wang W (2013) The application of MR imaging in the detection of hip involvement in patients with ankylosing spondylitis. Eur J Radiol 82(9):1487–1493.  https://doi.org/10.1016/j.ejrad.2013.03.020 CrossRefPubMedGoogle Scholar
  3. 3.
    Zou YC, Yang XW, Yuan SG, Zhang P, Li YK (2016) Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro. Drug Des Devel Ther 10:933–948.  https://doi.org/10.2147/DDDT.S97463 PubMedGoogle Scholar
  4. 4.
    Sakellariou G, Iagnocco A, Meenagh G, Riente L, Filippucci E, Delle Sedie A, Scirè CA, Bombardieri S, Grassi W, Valesini G, Montecucco C (2012) Ultrasound imaging for the rheumatologist XXXVII. Sonographic assessment of the hip in ankylosing spondylitis patients. Clin Exp Rheumatol 30(1):1–5PubMedGoogle Scholar
  5. 5.
    Ungprasert P, Erwin PJ, Koster MJ (2017) Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Clin Rheumatol 36(7):1569–1577.  https://doi.org/10.1007/s10067-017-3693-7 CrossRefPubMedGoogle Scholar
  6. 6.
    Nystad TW, Furnes O, Havelin LI, Skredderstuen AK, Lie SA, Fevang BT (2014) Hip replacement surgery in patients with ankylosing spondylitis. Ann Rheum Dis 73(6):1194–1197.  https://doi.org/10.1136/annrheumdis-2013-203963 CrossRefPubMedGoogle Scholar
  7. 7.
    Chen MH, Lee MH, Liao HT, Chen WS, Lai CC, Tsai CY (2018) Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. Clin Rheumatol 37(2):429–438.  https://doi.org/10.1007/s10067-017-3965-2 CrossRefPubMedGoogle Scholar
  8. 8.
    Li J, Wang X, Han Z, Zhang Y, Wang Y, Zhang Y, Li W (2016) Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. Int J Immunopathol Pharmacol 29(3):510–515.  https://doi.org/10.1177/0394632016656013 CrossRefPubMedGoogle Scholar
  9. 9.
    Lian F, Yang X, Liang L, Xu H, Zhan Z, Qiu Q, Ye Y (2012) Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int 32(6):1663–1667.  https://doi.org/10.1007/s00296-011-1844-8 CrossRefPubMedGoogle Scholar
  10. 10.
    Wu B, Song Y, Leng L, Bucala R, Lu LJ (2015) Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol 33(1):20–26PubMedGoogle Scholar
  11. 11.
    van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMedGoogle Scholar
  12. 12.
    Machado PM, Landewé R, Heijde DV, Assessment of SpondyloArthritis international Society (ASAS) (2018) Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 77(10):1539–1540.  https://doi.org/10.1136/annrheumdis-2018-213184 PubMedGoogle Scholar
  13. 13.
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 21(12):2286–2291PubMedGoogle Scholar
  14. 14.
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 21(12):2281–2285PubMedGoogle Scholar
  15. 15.
    Turan Y, Bayraktar K, Kahvecioglu F, Tastaban E, Aydin E, Kurt Omurlu I, Berkit IK (2014) Is magnetotherapy applied to bilateral hips effective in ankylosing spondylitis patients? A randomized, double-blind, controlled study. Rheumatol Int 34(3):357–365.  https://doi.org/10.1007/s00296-013-2941-7 CrossRefPubMedGoogle Scholar
  16. 16.
    Tiwari A, Karkhur Y, Maini L (2018) Total hip replacement in tuberculosis of hip: a systematic review. J Clin Orthop Trauma 9(1):54–57.  https://doi.org/10.1016/j.jcot.2017.09.013 CrossRefPubMedGoogle Scholar
  17. 17.
    Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3–17.  https://doi.org/10.1136/annrheumdis-2017-211734 CrossRefPubMedGoogle Scholar
  18. 18.
    McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol 35(3):715–721.  https://doi.org/10.1007/s10067-014-2823-8 CrossRefPubMedGoogle Scholar
  19. 19.
    MacKay K, Brophy S, Mack C, Doran M, Calin A (2000) The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 27(12):2866–2872PubMedGoogle Scholar
  20. 20.
    Baraliakos X, Braun J (2010) Hip involvement in ankylosing spondylitis: what is the verdict? Rheumatology (Oxford) 49(1):3–4.  https://doi.org/10.1093/rheumatology/kep298 CrossRefGoogle Scholar
  21. 21.
    Wang D, Ma L, Wu D (2011) Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine 78(5):531–532.  https://doi.org/10.1016/j.jbspin.2011.03.023 CrossRefPubMedGoogle Scholar
  22. 22.
    Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, Brouwer E, Spoorenberg A (2015) Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol 33(2):174–180PubMedGoogle Scholar
  23. 23.
    Mörck B, Pullerits R, Geijer M, Bremell T, Forsblad-d'Elia H (2013) Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediat Inflamm 2013:289845.  https://doi.org/10.1155/2013/289845 CrossRefGoogle Scholar
  24. 24.
    Chingcuanco F, Segal JB, Kim SC, Alexander GC (2016) Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: a systematic review. Ann Intern Med 165(8):565–574.  https://doi.org/10.7326/M16-0428 CrossRefPubMedGoogle Scholar
  25. 25.
    Liu S, Rovine MJ, Molenaar PC (2012) Selecting a linear mixed model for longitudinal data: repeated measures analysis of variance, covariance pattern model, and growth curve approaches. Psychol Methods 17(1):15–30.  https://doi.org/10.1037/a0026971 CrossRefPubMedGoogle Scholar
  26. 26.
    Lin Z, Gu J, He P, Gao J, Zuo X, Ye Z, Shao F, Zhan F, Lin J, Li L, Wei Y, Xu M, Liao Z, Lin Q (2011) Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. Rheumatol Int 31(2):233–238.  https://doi.org/10.1007/s00296-009-1313-9 CrossRefPubMedGoogle Scholar
  27. 27.
    Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J (2011) The ankylosing spondylitis disease activity score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford) 50(8):1466–1472.  https://doi.org/10.1093/rheumatology/ker087 CrossRefGoogle Scholar
  28. 28.
    Zheng W, Li J, Zhao J, Liu D, Xu W (2014) Development of a valid simplified Chinese version of the Oxford hip score in patients with hip osteoarthritis. Clin Orthop Relat Res 472(5):1545–1551.  https://doi.org/10.1007/s11999-013-3403-y CrossRefPubMedGoogle Scholar
  29. 29.
    Vander Cruyssen B, Vastesaeger N, Collantes-Estévez E (2013) Hip disease in ankylosing spondylitis. Curr Opin Rheumatol 25(4):448–454.  https://doi.org/10.1097/BOR.0b013e3283620e04 CrossRefPubMedGoogle Scholar
  30. 30.
    Song R, Chung SW, Lee SH (2017) Radiographic evidence of hip joint recovery in patients with ankylosing spondylitis after treatment with anti-tumor necrosis factor agents: a case series. J Rheumatol 44(11):1759–1760.  https://doi.org/10.3899/jrheum.161401 CrossRefPubMedGoogle Scholar
  31. 31.
    Konsta M, Sfikakis PP, Bournia VK, Karras D, Iliopoulos A (2013) Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. Clin Rheumatol 32(8):1229–1232.  https://doi.org/10.1007/s10067-013-2263-x CrossRefPubMedGoogle Scholar
  32. 32.
    Verbruggen G (2006) Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 45(2):129–138CrossRefGoogle Scholar
  33. 33.
    Aguila Maldonado R, Ruta S, Valuntas ML, García M (2017) Ultrasonography assessment of heel entheses in patients with spondyloarthritis: a comparative study with magnetic resonance imaging and conventional radiography. Clin Rheumatol 36(8):1811–1817.  https://doi.org/10.1007/s10067-017-3723-5 CrossRefPubMedGoogle Scholar
  34. 34.
    Sudoł-Szopińska I, Znajdek M, Gietka P, Vasilevska-Nikodinovska V, Patrovic L, Salapura V (2017) Imaging of juvenile spondyloarthritis. Part II: ultrasonography and magnetic resonance imaging. J Ultrason 17(70):176–181.  https://doi.org/10.15557/JoU.2017.0026 CrossRefPubMedGoogle Scholar
  35. 35.
    Chen D, Yuan S, Zhan Z, Xiao Y, Li H, Liang L, Yang X (2016) Early-stage hip involvement in patients with ankylosing spondylitis: a Chinese study based on magnetic resonance imaging. Mod Rheumatol 26(6):933–939.  https://doi.org/10.3109/14397595.2016.1153232 CrossRefPubMedGoogle Scholar
  36. 36.
    Hermann KG, Bollow M (2014) Magnetic resonance imaging of sacroiliitis in patients with spondyloarthritis: correlation with anatomy and histology. Rofo 186(3):230–237.  https://doi.org/10.1055/s-0033-1350411 PubMedGoogle Scholar
  37. 37.
    Althoff CE, Sieper J, Song IH, Weiß A, Diekhoff T, Haibel H, Hamm B, Hermann KG (2016) Comparison of clinical examination versus whole-body magnetic resonance imaging of enthesitis in patients with early axial spondyloarthritis during 3 years of continuous etanercept treatment. J Rheumatol 43(3):618–624.  https://doi.org/10.3899/jrheum.150659 CrossRefPubMedGoogle Scholar
  38. 38.
    Cantarini L, Fabbroni M, Talarico R, Costa L, Caso F, Cuneo GL, Frediani B, Faralli G, Vitale A, Brizi MG, Sabadini L, Galeazzi M (2015) Effectiveness of adalimumab in non-radiographic axial spondyloarthritis: evaluation of clinical and magnetic resonance imaging outcomes in a monocentric cohort. Medicine (Baltimore) 94(30):e1170.  https://doi.org/10.1097/MD.0000000000001170 CrossRefGoogle Scholar
  39. 39.
    Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225.  https://doi.org/10.1002/art.30393 CrossRefPubMedGoogle Scholar
  40. 40.
    Lee H, Jung Y, Song S, Lee J, Shim H, Kang W, Kim E (2017) Dosage and duration of etanercept therapy for ankylosing spondylitis: a meta-analysis. Int J Technol Assess Health Care 33:69–75.  https://doi.org/10.1017/S0266462317000150 CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Department of Rheumatology and ImmunologyGuangdong Second Provincial General HospitalGuangzhouChina
  2. 2.Department of Medical ImagingGuangdong Second Provincial General HospitalGuangzhouChina

Personalised recommendations